Introduction
Vaccination with attenuated rubella virus now makes congenitally acquired rubella a potentially preventable disease, and in the U.K. it is official policy to offer vaccination to 11-14-year-old schoolgirls (Department of Health and Social Security, 1970) . Though routine rubella vaccination of women of child-bearing age is not advised it is recommended for women at special risk of acquiring rubella-for example, nurses and schoolteachers (Department of Health and Social Security, 1972) . Because the teratogenicity of the current attenuated vaccines is unknown, however, vaccinees must not become pregnant for at least two months after vaccination (Department of Health and Social Security. 1970) . Despite this warning many terminations have been carried out because of inadvertant vaccination during pregnancy (Center for Disease Control, 1973; Registrar General, 1973) . Furthermore, analysis of U.S. data shows that the im- Control, 1973) . Thus vaccines composed of strains that are not transmitted to the fetus, provided that they are still immunogenic, would constitute a major advance in the development of rubella vaccines.
Some Japanese workers claim that though the pattern of postnatally acquired rubella in Japan is similar to that in most western countries congenitally acquired disease is rare, and they have attributed this tothe fact that Japanese strains are of reduced teratogenicity (Kono et al., 1969) . In vitro studies have shown that when compared with U.S.-derived strains with a similar passage history Japanese strains induce significantly higher levels of interferon in primary human placental cell cultures but not in fetal lung cultures or leucocyte preparations (Banatvala et al., 1971; Potter et al., 1973) . One of these Japanese strains, To-336, has been attenuated by passage in primary guinea-pig kidney cell cultures and undergone preliminary trials in Japan (R Kono, personal communication (Feldman, 1968; Cooper et al., 1969) . Altogether 150 (22.2%) were seronegative, 142 of whom participated in the trial. After signing a consent form each subject was allocated at random to one of four groups, each of which was allocated one of the following vaccines: Cendehill (Huygelen and Peetermans, 1967) , HPV77. DE-5 (Buynak et al., 1968) , RA27/3 (Plotkin et al., 1965) (table II) . Though the majority of rubella virus isolations had titres of < 10 0'-5 TCD,0/041 ml, 11 (20%) of the 55 samples titrated had titres > 101-5TCD50/0 1 ml. Virus was most often isolated between days 8 and 14 with To-336, RA27/3, and Cendehill vaccines but with HPV77. DE-5 vaccine virus was most often isolated between days 15 and 21 (table III) .
REACTIONS
Joint symptoms occurred frequently with the HPV77. DE-5 (38'7%) and RA27/3 (41 7%) vaccines, less often with Cendehill vaccine (22 9%) and were least common with To-336 (17-6%) vaccine (table IV) . These differences however, were not statistically significant (P >005). Multiple joint involvement and arthritis-that is, joint swelling or limitation of movement or both-were more often encountered with the HPV77. DE-5 vaccine (table V) . Nevertheless, the incidence of arthritis with this vaccine did not differ significantly from that induced by the RA27/3 or To-336 vaccine (P >0 05), but the Cendehill vaccine caused a significantly lower incidence of arthritis than did the HPV77. DE-5 vaccine (P <0-01). The knees, fingers, metacarpophalangeal joints, and wrists were most commonly involved ( Rash occurred in 9 (25%) of the 36 vaccinees given RA27/3 vaccine. The rashes were faint, macular, and usually fleeting; rash was less often encountered with the other vaccines (table  IV) . One 18-year-old nurse developed erythema, oedema, and itching at the site of inoculation within seven hours of vaccination with RA27/3 vaccine, which responded to treatment with oral chlorpheniramine.
The overall incidence of malaise, sore throat, and lymphadenopathy was similar in the control and vaccinated groups. (Best and Banatvala, 1967) . Perhaps attenuation results in some alteration of the biological properties of the virus whereby it replicates less favourably in the respiratory mucosa of susceptible contacts (Dudgeon et al., 1969) .
HPV77. DE-5 vaccine has been used extensively in the U.S.A. as well as other parts of the world but clinical trials in adults in the U.K., though involving relatively small numbers, showed that this vaccine caused joint symptoms more often than did RA27/3 and Cendehill vaccines (Dudgeon et al., 1969) . Our results, however, show a similar incidence of joint symptoms after vaccination with RA27/3 and HPV77. DE-5 vaccines, though HPV77. DE-5 vaccine produced rather more severe symptoms. Other workers have suggested that joint symptoms may be related to hormonal factors since they occur less often before puberty (International Conference on Rubella Immunization, 1969) and in those vaccinated post partum (Horstmann et al., 1970) . Swartz et al. (1971) showed a significantly greater incidence of joint symptoms in those vaccinated within five days of the onset of menstruation than in those vaccinated six to 24 days after its onset. We were unable to confirm this finding (table VIII) but, in contrast, were able to show that joint symptoms are most likely to occur within seven days of the onset of menstruation. Since joint symptoms occurred most often 13 to 21 days after vaccination it should be possible to reduce their incidence significantly by vaccinating adult women in the last seven days of their cycle. Though Weibel et al. (1969) suggested that oral contraceptives protected against joint symptoms we were unable to confirm this, and our results are therefore in agreement with those of Monto et al. (1970) and Lerman et al. (1971) .
We feel that our results are sufficiently encouraging to justify more extensive trials with the To-336 vaccine. This vaccine would, of course, have a considerable advantage if it were not transmitted to the fetus, but this could be determined only by examining the products of conception of seronegative women given To-336 vaccine who were due for therapeutic abortion for other reasons, or by examining the conceptuses of women inadvertently vaccinated with this vaccine during pregnancy. In our opinion the former method would raise considerable ethical problems and data could be accumulated only by the latter method if To-336 vaccine were used extensively over a prolonged period. Though Kono et al. (1969) showed that Japanese rubella viruses, including the To-336 strain, were not transmitted to rabbit fetuses whereas U.S.-derived strains were, we were unable to confirm these results (J. E. Potter and J. E. Banatvala, unpublished data) .
At present an assessment of the teratogenicity of Japanese rubella virus strains in man can be made only indirectly by epidemiological methods, and one of us (J.E.B.) recently visited Japan to obtain as much information as possible at first hand.
Rubella was prevalent in many parts of Japan between 1965 and 1970; however, a questionnaire designed to assess the incidence of congentially acquired rubella during the five-year period, sent at the end of December 1970 to the paediatric, ophthalmic, and otolaryngology departments of 950 general hospitals throughout the country, resulted in only 47 cases being notified, most of which occurred in southern Japan (R. Kono, personal communication) . This contrasts with data provided by the National Congenital Rubella Surveillance Programme in the U.K. Thus in the U.K., which has a population about half that of Japan, it is estimated that about 200 cases of congenitally acquired rubella occur during a non-epidemic year, though only about 25% are actually reported during that particular year (W. Marshall, personal communication). Nevertheless, differences in the incidence of congenital rubella may only reflect the efficiency of the two methods of survey, many cases in Japan, particularly in remote areas, remaining undiagnosed or if diagnosed not reported. About half of the Japanese hospitals approached, however, had virological facilities, and those that did not had access to them elsewhere.
A further explanation which might account for the apparent rarity of congenital rubella in Japan could be that most women of child-bearing age are already immune, particularly since Japanese women tend to marry and bear children at a rather later age than in many western countries. It has been shown, however, that during the child-bearing period of 19-29 years of age the proportion of seronegative women varies from 13% to 23% in the southern prefectures and from 9% to 14% in the northern ones (Committee of Rubella Epidemiological Study, 1971) , confirming that the proportion of seronegative women of child-bearing age is indeed similar to that in most western countries.
It is also possible that Japanese women differ biologically in their response to rubella virus. The island of Okinawa, however, with a population of 933,800, most of whom are Japanese, experienced an extensive rubella epidemic in 1965 which resulted in the birth of 352 rubella-affected babies (Hirayama, 1970) . Kono et al. (1971) suggested that the high incidence of congenital deformities may have arisen from the importation of U.S.-derived rubella strains which spread from U.S. military bases to the indigenous population. Though Hirayama (1970) suggested that the proportion of rubella-susceptible women (40%) was largely responsible for the large number of congenitally acquired infections and that the low incidence of congenital rubella on the mainland resulted from most adult women being already immune, this suggestion is not supported by the seroepidemiological studies quoted above.
Whether congenitally acquired rubella is really rare in Japan and if it is whether this is because Japanese rubella virus strains are not transmitted to the fetus cannot be determined at present. We, however, feel that data accumulated so far should encourage Japanese workers to develop a longitudinal surveillance programme on a national basis, all possible cases of congenitally acquired infection being referred centrally for both clinical and virological assessment as is the case in the U.K. and the U.S.A.
